Rafael Amado
age ~75
from Santa Rosa, CA
- Also known as:
-
- Amado Rafael
Rafael Amado Phones & Addresses
- Santa Rosa, CA
- San Francisco, CA
Resumes
Rafael Amado
view source
Rafael Amado
view sourceLocation:
San Francisco, CA
Rafael Franco Amado
view source
Rafael Amado
view sourceLocation:
United States
News
FDA Grants T-Cell Therapy Breakthrough Designation in Sarcoma
view source- e are pleased that the FDA has granted breakthrough therapy designation for our T-cell therapy in synovial sarcoma, recognizing both the unmet need for patients suffering from this disease as well as the promise of these early data, said Rafael Amado, MD, chief medical officer at Adaptimmune. We l
- Date: Feb 09, 2016
- Category: Health
- Source: Google
Adaptimmune wins 'breakthrough' tag
view source- "We are pleased that the FDA has granted breakthrough therapy designation for our T-cell therapy in synovial sarcoma, recognizing both the unmet need for patients suffering from this disease as well as the promise of these early data," said Rafael Amado, Adaptimmune's chief medical officer. "We look
- Date: Feb 09, 2016
- Category: Health
- Source: Google
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptim...
view source- re pleased that the FDA has granted Breakthrough Therapy designation for our T-cell therapy in synovial sarcoma, recognizingboth the unmet need for patientssuffering from this disease as well asthe promise of these early data, saidDr. Rafael Amado, Adaptimmunes Chief Medical Officer.We look
- Date: Feb 09, 2016
- Category: Health
- Source: Google
Scheduled Conference Calls, License Agreements, Dividends, Preliminary ...
view source- patients during the first four cycles of treatment. Dr. Rafael Amado, Senior Vice President Oncology R&D at GSK, said, "Cytopenias are important complications of MDS which tend to worsen with azacitidine treatment. Currently, there are no approved treatments for MDS that stimulate platelet production.
- Date: Jun 30, 2014
- Category: Business
- Source: Google
GSK and Genmab announce top-line results from a Phase III study of ...
view source- scientific community as soon it became available. We will now work to further analyse the data and to better understand the totality of the efficacy and safety findings," said Dr. Rafael Amado, Head of Oncology R&D at GSK. "We are very grateful to the CLL patients who participated in this trial.
- Date: Jun 27, 2014
- Category: Health
- Source: Google
Glaxo's Arzerra Lukemia Drug Misses Key Target in Clinical Trial
view source- It was our priority to share this result with the scientific community as soon as it became available, said Dr. Rafael Amado, head of oncology R&D at Glaxo. We will now work to further analyze the data and to better understand the totality of the efficacy and safety findings.
- Date: Jun 27, 2014
- Category: Health
- Source: Google
Tykerb, Avastin suffer disappointing data at SABCS
view source- had a slightly improved rate of progression-free survival, the difference when compared with placebo wasn't statistically significant. "Although we are disappointed,"GSK SVP Rafael Amado said, "[Tykerb] remains an important treatment option for patients with metastasis HER2-positive breast cancer."
- Date: Dec 09, 2011
- Category: Health
- Source: Google
Googleplus
Rafael Amado
Rafael Amado
Rafael Amado
Rafael Amado
view source
Jaime Rafael Amado Pinto
view source
Rafael Amado Aquino Paredes
view source
Rafael Amado Snchez
view source
Rafael Amado
view source
Rafael Amado
view source
Cesar Rafael Amado Muoz
view source
Rafael Amado
view sourceFlickr
Youtube
Get Report for Rafael Amado from Santa Rosa, CA, age ~75